Registry update — unassessed
Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity Study (PEARL): A Prospective, Double-Blind, Placebo-Controlled Trial for Rapamycin in Healthy Individuals Assessing Safety and Efficacy in Reducing Aging Effects
Trial registry update: COMPLETED. No results reported in the supplied registry record.
RCTRoutine significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Jan 24, 2024 · Discovered: Sep 19, 2026 · Assessed: — · Historical research backfill
What it does not prove
- The abstract provides no information on which clinical aging measures were assessed or whether rapamycin had any effect on them
- No data are reported on safety outcomes, adverse events, or tolerability
- The sample size, participant characteristics, and follow-up duration are not disclosed, limiting assessment of generalizability or study quality
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Healthy older adult population
- Primary outcome
- Safety and efficacy in reducing clinical measures of aging
- Effect size
- —
- Significance
- Not reported
- Journal
- AgelessRx
- Published
- Jan 24, 2024
Sources
Primary source
- AgelessRx ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
This is a randomized, placebo-controlled trial into the safety and efficacy in reducing clinical measures of aging in an older adult population.
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.